Novartis announced 12 Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) and Atectura Breezhaler [indacaterol acetate and mometasone furoate [IND/MF] abstracts to be presented at the upcoming European Respiratory Society (ERS) International Congress 2021, taking place virtually from September 5 – September 8, 2021.
Novartis announced that high-dose, once-daily Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) significantly reduces both moderate-or-severe and severe asthma exacerbation rates in patients whose asthma is uncontrolled on medium- or high-dose long-acting beta2-agonist (LABA)/inhaled corticosteroids (ICS), when compared with a once-daily medium-dose of the same treatment.
A high dose of Novartis' Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate/IND/GLY/MF) significantly reduced asthma exacerbations compared to a medium dose, shows a new analysis.
Novartis Phase III IRIDIUM data in Lancet Respiratory Medicine show benefit of Enerzair® Breezhaler® (QVM149), the first-in-class inhaled LABA/LAMA/ICS combination in uncontrolled asthma